Abstract / Summary
KRAS-inhibitor resistance creates a need to distinguish genes worth investigating from genes already supported as selective therapeutic targets. This note assesses NEB, NR1D1, TECTA, USP36 and ZNF512 using a frozen set of recovered public sources. Exact native-symbol coverage, descriptive RNA contrasts, baseline genetic fitness, prior biological knowledge and source-specific limitations are considered separately. None of the five candidates is promoted to a validated new therapeutic target. NEB, NR1D1, TECTA and ZNF512 remain unvalidated hypotheses; USP36 is excluded from selective new-target promotion in this evidence set because its broad baseline essentiality does not support that claim. ZNF512 has concordant downward descriptive RNA contrasts in two pancreatic-cell source contexts, but neither these contrasts nor an existing predicted structure establish resistance-specific dependency. Two pinned Tahoe processed-expression rows have adjusted p-values of 0.05191598 and 0.89710194, with the precise table comparator and upstream replicate construction unresolved. The contribution is a traceable account of candidate judgments and missing evidence, not an efficacy demonstration. The research continues beyond this frozen note. Not peer reviewed. The research remains active. This curated deposit contains an author-written note, candidate summary and source index, not raw third-party data or a complete executable reproducibility package.